» Articles » PMID: 26324805

Epidemiological Studies in Idiopathic Pulmonary Fibrosis: Pitfalls in Methodologies and Data Interpretation

Overview
Journal Eur Respir Rev
Specialty Pulmonary Medicine
Date 2015 Sep 2
PMID 26324805
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Data on incidence, prevalence and mortality of idiopathic pulmonary fibrosis (IPF) are sparse and vary across studies. The true incidence and prevalence of the disease are unknown. In general, the overall prevalence and incidence reported in European and Asian countries are lower than those reported in American studies. In recent years, the epidemiological approach to IPF has been difficult for many reasons. First, the diagnostic criteria of the disease have changed over time. Secondly, the coding system used for IPF in administrative databases, the most common data source used to study this aspect of the disease, has been modified in the past few years. Finally, the study design, the methodology and the population selected in each of the studies are very different. All these aspects make comparisons among studies very difficult or impossible. In this review, we list the main issues that might arise when comparing different studies and that should be taken into consideration when describing the state of epidemiological knowledge concerning this pathology.

Citing Articles

Cellular therapies for idiopathic pulmonary fibrosis: current progress and future prospects.

Le N, Dunleavy M, Kumar R, Zhou W, Bhatia S, El-Hashash A Am J Stem Cells. 2024; 13(4):191-211.

PMID: 39308764 PMC: 11411253. DOI: 10.62347/DAKS5508.


Mechanical ventilation in patients with idiopathic pulmonary fibrosis in Korea: a nationwide cohort study.

Sim J, Moon S, Choi J, Oh J, Lee Y, Min K Korean J Intern Med. 2024; 39(2):295-305.

PMID: 38326962 PMC: 10918379. DOI: 10.3904/kjim.2023.273.


Chronic pulmonary fibrosis alters the functioning of the respiratory neural network.

Yegen C, Marchant D, Bernaudin J, Planes C, Boncoeur E, Voituron N Front Physiol. 2023; 14:1205924.

PMID: 37383147 PMC: 10293840. DOI: 10.3389/fphys.2023.1205924.


Nanotherapeutic Approaches to Treat COVID-19-Induced Pulmonary Fibrosis.

Kanvinde S, Deodhar S, Kulkarni T, Jogdeo C BioTech (Basel). 2023; 12(2).

PMID: 37218751 PMC: 10204512. DOI: 10.3390/biotech12020034.


Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study.

Jovanovic D, Sterclova M, Mogulkoc N, Lewandowska K, Muller V, Hajkova M Respir Res. 2022; 23(1):135.

PMID: 35624513 PMC: 9145164. DOI: 10.1186/s12931-022-02033-6.


References
1.
von Plessen C, Grinde O, Gulsvik A . Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med. 2003; 97(4):428-35. DOI: 10.1053/rmed.2002.1466. View

2.
Hodgson U, Laitinen T, Tukiainen P . Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax. 2002; 57(4):338-42. PMC: 1746288. DOI: 10.1136/thorax.57.4.338. View

3.
Panos R, Mortenson R, Niccoli S, King Jr T . Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med. 1990; 88(4):396-404. DOI: 10.1016/0002-9343(90)90495-y. View

4.
Thomeer M, Demedts M, Vandeurzen K . Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg. 2001; 56(3):163-72. DOI: 10.1179/acb.2001.026. View

5.
Olson A, Swigris J, Lezotte D, Norris J, Wilson C, Brown K . Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med. 2007; 176(3):277-84. DOI: 10.1164/rccm.200701-044OC. View